Skip to content
‹ Back to IndustriesHealthcare

Technology and Oncology Podcast Powered by Carevive

The OCM (Oncology Care Model), launched in 2016, is a payment model designed to help oncology centers transition from the traditional Medicare Fee-for-Service (FFS) payment structure and focus on high-value care. The EOM (Enhancing Oncology Model) is the next phase model and will replace OCM starting July 1, 2023. EOM will support clinicians caring for…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share
Technology and Oncology Podcast Powered by Carevive

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The OCM (Oncology Care Model), launched in 2016, is a payment model designed to help oncology centers transition from the traditional Medicare Fee-for-Service (FFS) payment structure and focus on high-value care.

The EOM (Enhancing Oncology Model) is the next phase model and will replace OCM starting July 1, 2023. EOM will support clinicians caring for patients with seven common cancer types, focusing on health equity and accountable, affordable care.

But what are the revenue-enhancing opportunities in EOM, is it worth the transition from OCM, and what does it actually provide?

On today’s episode of Technology and Oncology Podcast, host Michelle Dawn Mooney speaks with John Elliot, the Vice President of Sales at Carevive to discuss how oncology centers and clinics can transition from OCM to EOM and how they can get assistance for the process.

Michelle Dawn Mooney and John Elliot discussed:

  1. What clients should expect after approval and assistance available to meet the July 1 deadline for launching
  2. Benefits of EOM to oncology patients
  3. Where people can find more information and assistance on the topic

“Looking at oncology, efficiency is key, however, there are limited constrained resources. 24/7 access to electronic records, having a line of communication, capturing symptoms at the right time, access to care with the focus of addressing challenges in the oncology and health care sector which can improve patient outcome and reduce cost – this is what the EOM aims to achieve. The EOM model bridges the gap of communication and ensures members of the care team are aware of what is happening in real-time, which promotes standardization of care,” explained John Elliot.

John Elliot is the Vice President of Sales at Carevive. He received his Bachelor of Arts degree in Advertising from Southern Methodist University and his Master of Business Administration from Washington University in St. Louis-Olin Business School. He has over ten years of experience working with oncology centers.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Caris launches blood-based treatment response monitoring as Q3 revenue rises 27%

Caris launches blood-based treatment response monitoring as Q3 revenue rises 27%

Caris Life Sciences completed approximately 61,500 clinical cases in Q3 2026 and raised 2026 revenue guidance to $1.04-$1.05 billion. Caris Assure is now available for therapeutic response monitoring, and Caris Confirm, a minimal residual disease assay, is targeted to launch before year-end.

  • 01Caris said higher operating expenses were driven primarily by headcount-related costs, research and development investment and marketing.
  • 02Caris Assure is now available for therapeutic response monitoring, and Caris Confirm, a whole genome, tumor-informed assay for minimal residual disease, is targeted to launch before year-end.
  • 03Caris reaffirms its guidance for clinical therapy selection volume growth of approximately 20%.

Nov 8, 2026

Denials get a queue, underpayments just look like paid claims

Denials get a queue, underpayments just look like paid claims

Underpayments in healthcare revenue cycle operations lack the visibility of denied claims because they don't trigger alerts or queue workflows. Without dedicated ownership and line-level verification against contract terms, paid claims that fall short of their contractual amount pass through undetected.

  • 01Denial workflows activate on rejection events, but underpayments produce no event, leaving paid claims unverified by default.
  • 02The speaker says many provider groups lack line-level contract intelligence to check each paid line against the applicable terms.
  • 03Payment received and payment checked are separate tasks: one verifies acceptance, the other verifies correctness—and the second often has no assigned owner.

Nov 6, 2026

A zero-paid claim line is not automatically an underpayment

A zero-paid claim line is not automatically an underpayment

A zero payment on a claim line isn't automatically an underpayment; contract terms, particularly packaging rules, determine whether zero is correct. Chasing unsupported findings damages credibility with payers and weakens the position of legitimate disputes, so revenue cycle teams must verify the full contract terms and effective dates before treating any payment difference as a finding.

  • 01When a contract packages add-ons into the primary procedure, the add-on line may legitimately show zero payment because it is folded into the primary procedure reimbursement.
  • 02Pursuing payment differences that lack contract support burns credibility with payers and can weaken the team’s position on later disputes, including valid ones.
  • 03Always verify the complete contract terms, fee schedules, carve-outs, amendments, and the specific version in effect on the date of service before treating a payment variance as a recoverable underpayment.

Nov 6, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512